Grufity logo
Grufity logo
PCSA

PCSA - Processa Pharmaceuticals, Inc. Stock Price, Fair Value and News

$2.10-0.11 (-4.98%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

PCSA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PCSA Price Action

Last 7 days

-9.1%

Last 30 days

-25.7%

Last 90 days

-30.4%

Trailing 12 Months

-66%

PCSA RSI Chart

PCSA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PCSA Valuation

Market Cap

5.9M

Price/Earnings (Trailing)

-0.42

Price/Sales (Trailing)

1.4K

EV/EBITDA

-0.31

Price/Free Cashflow

-0.48

PCSA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PCSA Fundamentals

PCSA Revenue

Revenue (TTM)

5.0K

PCSA Earnings

Earnings (TTM)

-14.1M

Earnings Growth (Yr)

-19.95%

Earnings Growth (Qtr)

-1.22%

PCSA Profitability

EBT Margin

-271276.68%

Return on Equity

-556.08%

Return on Assets

-312.53%

Free Cashflow Yield

-207.59%

PCSA Investor Care

Shares Dilution (1Y)

1170.50%

Diluted EPS (TTM)

-6.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2016100.7K80.7K22.5K5.0K
2015113.8K120.4K126.9K133.5K
2014313.7K329.3K256.0K107.2K
2013222.2K252.3K282.4K312.5K
2012---192.1K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Processa Pharmaceuticals, Inc.

PCSA
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytidine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.
 CEO
 WEBSITEprocessapharmaceuticals.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Processa Pharmaceuticals, Inc. Frequently Asked Questions

PCSA is the stock ticker symbol of Processa Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Processa Pharmaceuticals, Inc. is 5.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, PCSA's PE ratio (Price to Earnings) is -0.42 and Price to Sales (PS) ratio is 1.37 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCSA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Processa Pharmaceuticals, Inc. has provided -0.56 (multiply by 100 for percentage) rate of return.